Alison D. Silva
President, COO & DirectorMs. Alison D. Silva, MA, MS, was the Chief Executive Officer, President and Consultant of Cotinga Pharmaceuticals Inc. (formerly known as Critical Outcome Technologies Inc.) since January 1, 2017, July 5, 2016 and 2013 respectively through August 2021. She serves on the Board of Directors of Cotinga Pharmaceuticals since May 14, 2015 and management consultant to several organizations, including EMA Wellness and The Orphan Group. Ms. Silva founded Synlogic, Inc. and served as its Executive Vice President and Chief Operating Officer since June 13, 2016. Ms. Silva is a Principal and Co-founder of Orphan Group. She served as a Vice President of Drug Development at Cequent Pharmaceuticals, Inc. Ms. Silva served as a Director of Development at Cequent Pharmaceuticals, Inc. Before joining Cotinga, Alison co-founded The Microbiome Company in 2013, later rebranded to Synlogic Therapeutics, where she served as Executive Vice President and Chief Operating Officer until June 2016. Other relevant positions include co-founder and Vice President, Development at Marina Biotech; co-founder and Director at The Orphan Group; Director, Drug Development at Cequent Pharmaceuticals; COO at SLA Pharma; and various other positions in biotech and pharma. At Cequent, Ms. Silva is responsible for the preclinical development of new therapeutic candidates, manufacturing oversight, regulatory issues and strategic development of the clinical platform and trial design. Ms. Silva served as Chief Operating Officer at SLA Pharma. She was Clinical Trials/Laboratory Manager at Pfizer where she was responsible for pre-approved cardiovascular indicated treatments, dealing primarily with clinical trial management, investigator and site initiation and regulatory/IRB submissions. She was responsible for a team of CRAs, study monitors and study coordinators, interfacing with therapeutic heads for clinical trial design and strategy. Prior to her tenure at Pfizer, Ms. Silva was Laboratory Manager of an infertility department at Massachusetts General Hospital (MGH) and Co-Principal Investigator and Study Head at the Cardiac Catheterization Laboratory of UMass-Worcester. She is a Board Member of Jupiter Neurosciences, Inc. (formerly Jupiter Orphan Therapeutics, Inc.) since November 30, 2018 and serves as its President since September 1, 2021 and was its Chief Business Officer since September 1, 2021 until June 5, 2026 and is its Chief Operating Officer since June 5, 2026. She has served as an independent director at Jupiter Neurosciences, Inc. since September 8, 2021. Ms. Silva received her undergraduate degree from Clark University in 2001 and an M.S. degree from UMass Medical Center. She holds a BA in Biology and Mathematics from Clark University in 2001 and an MS from Clark University and University of Massachusetts Medical Center in 2002. She serves on the board of Gene Spotlight, Inc., where she is co-foundersince April 2011. Since 2016, Ms. Brady has served on the Board of Advisors at University of Pennsylvania’s school of Social Policy & Practice and is currently the Fundraising Chair of its Power of Penn campaign. She received a BAS from University of Pennsylvania in 1993. She also received a PR Strategy Certificate in 2021 from Cornell University.
Positions
- Company NameJupiter Neurosciences, Inc.Stock CodeJUNSPositionPresident, COO & DirectorColleagues
- CRChrister RosenCo-Founder, CEO & Chairman of the Board
- MHMarshall HaywardCo-Founder, Chief Scientific Officer & Director
- ARAlexander RosenCo-Founder & Chief Administrative Officer
- SESaleem ElmasriCFO & Secretary
- CWClaes WahlestedtCo-Founder, Co-Chairman of Scientific Advisory Board & Consulting Chief Medical Officer
- NHNicholas H. HemmerlyIndependent Director
